Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.
Rompoti N, Koumprentziotis IA, Stefanaki I, Vavouli C, Papoutsaki M, Politou M, Panagakis P, Befon A, Kousta F, Lazou E, Chasapi V, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: panagakis p. Arch Dermatol Res. 2024 Oct 9;316(9):667. doi: 10.1007/s00403-024-03419-w. Arch Dermatol Res. 2024. PMID: 39382588 No abstract available.
A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A, Panagakis P, Moustou E, Vergou T, Kallidis P, Mandekou-Lefaki I, Chaidemenos G, Sotiriadis D, Alexopoulou G, Haratsis Y, Antoniou C. Petridis A, et al. Among authors: panagakis p. J Eur Acad Dermatol Venereol. 2018 May;32(5):768-775. doi: 10.1111/jdv.14802. J Eur Acad Dermatol Venereol. 2018. PMID: 29356149
Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E, Vavouli C, Politou M, Befon A, Kostakis P, Rigopoulos D, Nicolaidou E. Rompoti N, et al. Among authors: panagakis p. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1240-1247. doi: 10.1111/jdv.16202. Epub 2020 Feb 28. J Eur Acad Dermatol Venereol. 2020. PMID: 31953892
Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra-patient, left-to-right prospective study.
Gregoriou S, Sidiropoulou P, Tsimpidakis A, Rompoti N, Tsironi T, Panagakis P, Polydorou D, Kostakis P, Rigopoulos D. Gregoriou S, et al. Among authors: panagakis p. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e519-e520. doi: 10.1111/jdv.16426. Epub 2020 May 6. J Eur Acad Dermatol Venereol. 2020. PMID: 32259356 No abstract available.
Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined Dermatology-Rheumatology clinic: a retrospective real-world study.
Klavdianou K, Stavropoulou M, Panagakis P, Papoutsaki M, Panagiotopoulos A, Koutsianas C, Stratigos A, Rigopoulos D, Vassilopoulos D. Klavdianou K, et al. Among authors: panagakis p. Rheumatol Int. 2022 Jun;42(6):1035-1041. doi: 10.1007/s00296-022-05126-z. Epub 2022 Apr 18. Rheumatol Int. 2022. PMID: 35435445
Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D, Angelakopoulos C, Apalla Z, Georgiou S, Delli F, Drosos A, Zafiriou E, Katsantonis J, Lazaridou E, Panagakis P, Papadavid E, Papakonstantis M, Roussaki-Schulze AV, Sotiriou E, Anastasiadis G, Tampouratzi E, Chasapi V, Sfaelos K, Ioannides D; BrIDGE Study Group. Rigopoulos D, et al. Among authors: panagakis p. Dermatol Ther. 2022 Dec;35(12):e15886. doi: 10.1111/dth.15886. Epub 2022 Nov 1. Dermatol Ther. 2022. PMID: 36184757
The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.
Tsiogka A, Gregoriou S, Stratigos A, Soulaidopoulos S, Rompoti N, Panagakis P, Papoutsaki M, Kostakis P, Kontochristopoulos G, Tsioufis K, Campanati A, Offidani A, Vlachopoulos C, Rigopoulos D. Tsiogka A, et al. Among authors: panagakis p. Biomedicines. 2023 Jan 23;11(2):318. doi: 10.3390/biomedicines11020318. Biomedicines. 2023. PMID: 36830855 Free PMC article. Review.
Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Rigopoulos D, Tampouratzi E, Angelakopoulos C, Apalla Z, Barkis I, Georgiou S, Delli F, Drosos A, Zafiriou E, Katsantonis J, Lazaridou E, Panagakis P, Papadavid E, Papakonstantis M, Roussaki-Schulze AV, Sotiriou E, Anastasiadis G, Chasapi V, Sfaelos K, Ioannides D; BrIDGE Study Group. Rigopoulos D, et al. Among authors: panagakis p. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):1121-1130. doi: 10.1111/jdv.19816. Epub 2024 Feb 3. J Eur Acad Dermatol Venereol. 2024. PMID: 38308561
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Rompoti N, Stefanaki I, Panagakis P, Papoutsaki M, Politou M, Vavouli C, Befon A, Kousta F, Lazou E, Zaimi M, Koumprentziotis IA, Chasapi V, Rigopoulos D, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: panagakis p. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e1-e4. doi: 10.1111/jdv.19956. Epub 2024 Mar 20. J Eur Acad Dermatol Venereol. 2025. PMID: 38506605 No abstract available.
19 results